In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

John Hodgson

Data Editor, Pharma

Cambridge, U.K
John is Data Editor, Pharma within Informa’s Pharma Intelligence division. He honed skills as a writer, analyst and consultant, commentating on science and business in biotechnology over three decades. He prefers evidence to received wisdom, and believes that new is interesting but improved is better.
Advertisement
Set Alert for Articles By John Hodgson

Latest From John Hodgson

Unsuccessful IPOs

Not all initial public offerings are taken up, even in the best of funding years. Of the 54 life sciences IPOs registered in 1997, 11 (20%) were withdrawn because of pricing issues or lack of interest.

BioPharmaceutical Deals

Amazon Versus Biotech: How The IPO Class Of '97 Worked Out

Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16 IPO window. To understand what may be in store for those firms and their backers, In Vivo reexamines the fate of a previous generation of companies, the IPO Class of 1997.

Financing Growth

Try, Try Again: Bain And Cinven File Fresh Bid For Stada

Stada is likely to approve a second takeover bid from equity groups Bain and Cinven soon, at a new price of €66.25 per share; an offer cleared by Germany's stock market authorities despite a ban in the country on repeat acquisition bids within 12 months.

M & A Generic Drugs

The End Of Generics Mergers? Too Much Effort, No Reward!

There has been $150bn worth of merger and acquisition activity since 2012 in the generic medicines arena, yet the sector is more fragmented than it was five years ago. CEOs and analysts from the generics sector believe that investor-propelled moves towards greater consolidation have been thwarted by the market agility of smaller companies. And now the cost of M&A has burdened major generics firms with debt.

Generic Drugs M & A

Biopharma Stocks June 2017: BIO’s Rallying Cry Gets A Response

In this month’s stock column, after the Nasdaq Biotech Index (NBI) shot up over 10% at end of June, Scrip focuses on the biopharma companies that propelled that surge. It looks as if investors have been influenced by the BIO Convention held in San Diego, the industry’s biggest forum for self-promotion.

Financing Analysis

Big Pharma May 2017: Product Developments Shift Stock

In a new monthly column, Scrip rounds up events on the stock market, noting trends and exceptional performance both good and bad. This month, the focus is on 30 biopharma companies with market caps above $10bn. Between them, these 30 companies account for approximately 75% of the asset value in the pharmaceutical industry.

Commercial Companies
See All
Advertisement
UsernamePublicRestriction

Register